Yeni bir glukosilceramid sentaz inhibitörü, sinükleinopatinin preklinik modellerinde alfa sinüklein patolojisini ve lizozomal disfonksiyonu zayıflatır.

A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.

Cosden M, Jinn S, Yao L, Gretzula CA, Kandebo M, Toolan D, Hatcher NG, Ma L, Lemaire W, Adam GC, Burlein C, Minnick C, Flick R, Watt ML, Mulhearn J, Fraley M, Drolet RE, Marcus JN, Smith SM.

Neurobiol Dis · 2021-09-09

DOI: 10.1016/j.nbd.2021.105507PMID: 34509608